Shenogen Pharma Group
PrivateLast Round
Series E
Extension
Sep 27, 2023
Total Funding Raised
$103.43M
Company Overview
Shenogen Pharma Group operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series E Extension round in September 2023.
Shenogen Pharma Group is a biopharmaceutical company that develops and commercializes first-in-class therapeutics for cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shenogen Pharma Group Comparables
Compare Shenogen Pharma Group with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| InnoCare Pharma Limited | 77% | |
| Evopoint Biosciences | 76% | |
| Zai Lab Limited | 74% |
For institutional investors. Book with your work email.
Shenogen Pharma Group Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E Extension | Sep 27, 2023 | ||||
| Strategic | Dec 1, 2019 | ||||
| Series C Extension | Apr 1, 2019 | ||||
| Series C Extension | Jan 1, 2019 | ||||
| Series C Extension | Jul 21, 2017 | ||||
Series B Extension | Dec 30, 2016 |
For institutional investors. Book with your work email.
Shenogen Pharma Group Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boxin Capital | Strategic |
| Beijing Jinhuitong Investment Management Co., Ltd. | Strategic |
| IDG Capital | Series B, Series C |
| Oriza Holdings | Series B |
| Zhongzhi Capital | Series C Extension |
| 和灵资本 | Series C Extension |
| Richlink Capital | Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 27, 2023
Raised Series E Extension round with Shenzhen New Henglida Capital Management.
- Dec 1, 2019
Raised a strategic round with multiple private equity and venture capital investors.
For institutional investors. Book with your work email.
Shenogen Pharma Group Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shenogen Pharma Group's valuation, stock price, and market status.
Is Shenogen Pharma Group a public or private company?
Shenogen Pharma Group is a private company.
What is the current stock price of Shenogen Pharma Group?
Shenogen Pharma Group is a private company, so its shares have no public market price. Caplight tracks Shenogen Pharma Group's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shenogen Pharma Group worth (valuation)?
Valuation information for Shenogen Pharma Group is not publicly available.
Can I buy Shenogen Pharma Group stock?
Shenogen Pharma Group shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shenogen Pharma Group's last funding round?
Shenogen Pharma Group's most recent funding round was Series E Extension on September 27, 2023.
Who are the main investors in Shenogen Pharma Group?
Key investors in Shenogen Pharma Group include Panlin Capital.
Will Shenogen Pharma Group IPO soon?
No public IPO plans have been announced for Shenogen Pharma Group.
How can I track Shenogen Pharma Group secondary market activity?
Caplight tracks bids, offers, and trades in Shenogen Pharma Group's shares on secondary markets.